Annuncio pubblicitario
Italia markets open in 8 hours 39 minutes

  • Dow Jones

    38.225,66
    +322,37 (+0,85%)
     

  • Nasdaq

    15.840,96
    +235,48 (+1,51%)
     

  • Nikkei 225

    38.236,07
    -37,98 (-0,10%)
     

  • EUR/USD

    1,0732
    +0,0014 (+0,13%)
     

  • Bitcoin EUR

    55.325,71
    +1.394,50 (+2,59%)
     

  • CMC Crypto 200

    1.278,82
    +8,07 (+0,64%)
     

  • HANG SENG

    18.207,13
    +444,10 (+2,50%)
     

  • S&P 500

    5.064,20
    +45,81 (+0,91%)
     

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus Biopharma Corporation
·2 minuto per la lettura
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation

WARMINSTER, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences:

H.C. Wainwright 25th Annual Global Investment Conference: Formal Presentation on September 12, 2023 at 3:30 pm ET

Baird’s 2023 Global Healthcare Conference: Fireside Chat on September 13, 2023 at 7:55 am ET

ANNUNCIO PUBBLICITARIO

To access the live webcast of the presentations please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. To address HBV, we are developing a RNAi therapeutic, an oral PD-L1 inhibitor, and an oral RNA destabilizer to potentially identify a combination regimen with the aim of providing a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. AB-729 is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronaviruses, (including SARS-CoV-2), for which we have nominated a compound and have begun IND-enabling pre-clinical studies. In addition, we are also exploring oncology applications for our internal PD-L1 portfolio. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com